Biovest International, Inc. (PINK:BVTI) has been quite disappointing over the past days. The stock has been either on the 
zero price change, or on the loss, unable to provoke traders’ attention. Yesterday, BVTI moved down again, though it looks like it hasn’t given up the fight for the climb.
Apparently, Biovest decided to cut off the loss by some fresh news. Just yesterday, the company reported that BiovaxID(R), its late-stage autologous active immunotherapy for the treatment of non-Hodgkin’s lymphoma was featured in an article published in the online version of Journal of Clinical Oncology. The vaccine is said to increase disease-free survival for follicular lymphoma patients in Biovest Phase III study.
The positive news was certainly meant to push up BVTI stock price, though the result is yet to be seen. In any case, the company has had not much luck on the market lately and it is desperate to finally hit the gain.
Biovest International is a biotechnology company focusing primarily on the development of BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma, or follicular NHL. At the beginning of this year, the company used to trade much higher than now, though since then the stock price has moved down significantly.[BANNER]
Unfortunately, its latest 10-Q report is not promising either. According to the 10-Q, the liabilities of Biovest are notably higher that its total assets and the company’s accumulated deficit exceeded $157 million. Besides, as of March 31 this year the stockholders’ deficit got over $31 million. In addition comes the long-term debt, along with the credit line of Biovest. Thus, its continuation turns out to be quite doubtful.
Based on all mentioned above, the featured articles about the company can hardly make it profitable.
